First @WazirXIndia hacked - $230 Millions
Now, @CoinDCX hacked - $44 Millions
And Government of #India is busy collecting 30% tax and 1% tds.
No regulation and no proper guidelines.
We are happy to share that Dr. Sushant Kumar, Senior Scientist at #ImmunoACT, recently delivered an inspiring lecture at @iitbombay to the National-level winners of Vidyarthi Vigyan Manthan (VVM) - India’s premier science talent program for VI-XI school students.
His talk, titled “Introduction to Gene Therapy: The Story of India’s First Approved Gene Therapy,” aimed to simplify the complex science behind gene therapy and share the incredible journey of #NexCAR19 - India’s first approved gene therapy, developed indigenously by IIT Bombay, @TataMemorial , and @ActImmuno .
Key highlights from the session:
✅ Basics of genes and gene therapy
✅ How gene therapy works - explained through simple, relatable examples
✅ The story behind NexCAR19, a groundbreaking CAR-T cell therapy developed in India
✅ Future of gene therapy, including innovative technologies like in vivo CAR-T therapy
The students were highly engaged, asking insightful questions about genetic technologies, immune cells, and the future of medical science.
At ImmunoACT, we strongly believe in nurturing scientific curiosity among young minds. We are committed to driving accessible, innovative therapies and sharing knowledge that can inspire future scientists and innovators.
#ImmunoACT #GeneTherapy #VVM #NexCAR19 #STEMEducation #CAR_T #Innovation #ScienceEducation #IITBombay #YoungScientists #India
Dr. @purwarrahul2, Founder, @ActImmuno and Prof. at @iitbombay referenced the journey behind NexCAR19- India's first #CAR-T cell therapy. Supported by strong global & academic partnerships, the therapy is now saving lives at a fraction of global costs, across 70+ hospitals.
#WorldBioproductDay2025BioE3Way
@DrJitendraSingh@rajesh_gokhale
🌟 Proud Moment! 🌟
We performed the first CAR-T cell therapy in Punjab and the northern Indian region for a patient with refractory B-ALL. This makes us one of the first few institutions in India to offer this level of treatment. @ActImmuno
Honoured to support the incredible team at DMCH in delivering Punjab’s first CAR-T cell therapy for a patient with relapsed leukemia and CNS involvement.
Huge thanks to Dr. Suvir Singh (@pb10_bmt) for leading the charge and sharing this milestone. From manufacturing to logistics and clinical guidance - grateful to be part of this milestone. Together, we’re pushing boundaries in Indian cancer treatment.
#CARTCellTherapy #ImmunoACT #CancerTreatment #MadeInIndia #BreakthroughTherapy